In:
American Journal of Hematology, Wiley, Vol. 95, No. 12 ( 2020-12), p. 1522-1530
Abstract:
Coagulopathy causes morbidity and mortality in patients with coronavirus disease 2019 (COVID‐19) due to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection. Yet, the mechanisms are unclear and biomarkers are limited. Early in the pandemic, we observed markedly elevated factor V activity in a patient with COVID‐19, which led us to measure factor V, VIII, and X activity in a cohort of 102 consecutive inpatients with COVID‐19. Contemporaneous SARS‐CoV‐2‐negative controls (n = 17) and historical pre‐pandemic controls (n = 260‐478) were also analyzed. This cohort represents severe COVID‐19 with high rates of ventilator use (92%), line clots (47%), deep vein thrombosis or pulmonary embolism (DVT/PE) (23%), and mortality (22%). Factor V activity was significantly elevated in COVID‐19 (median 150 IU/dL, range 34‐248 IU/dL) compared to contemporaneous controls (median 105 IU/dL, range 22‐161 IU/dL) ( P 〈 .001)—the strongest association with COVID‐19 of any parameter studied, including factor VIII, fibrinogen, and D‐dimer. Patients with COVID‐19 and factor V activity 〉 150 IU/dL exhibited significantly higher rates of DVT/PE (16/49, 33%) compared to those with factor V activity ≤150 IU/dL (7/53, 13%) ( P = .03). Within this severe COVID‐19 cohort, factor V activity associated with SARS‐CoV‐2 load in a sex‐dependent manner. Subsequent decreases in factor V were linked to progression toward DIC and mortality. Together, these data reveal marked perturbations of factor V activity in severe COVID‐19, provide links to SARS‐CoV‐2 disease biology and clinical outcomes, and nominate a candidate biomarker to investigate for guiding anticoagulation therapy in COVID‐19.
Type of Medium:
Online Resource
ISSN:
0361-8609
,
1096-8652
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1492749-4
Bookmarklink